Abstract
Unlike melanomas and colorectal cancers with a high tumor mutation burden, hypermutated gliomas generally do not respond to checkpoint blockade, a study concludes. Hypermutation shortens patient survival, and the results suggest that it occurs because of selective pressure from the chemotherapeutic temozolomide.
©2020 American Association for Cancer Research.
2020
American Association for Cancer Research.
You do not currently have access to this content.